Nepal suspends sale of Indian antibiotic injection drug Biotax 1 g due to health risks

Nepal’s drug regulator has suspended the sale and distribution of the antibiotic injection Biotax 1g, citing significant health risks. Laboratory tests by Nepal’s national drug regulator found that the injection, manufactured by Indian company Zydus Healthcare Ltd, did not meet required manufacturing standards.

According to a report by The Wire, “We have directed the manufacturing company, importers and distributors to stop the sale, import and distribution of the said drug until further notice,” said Pramod KC, spokesperson for the department.

Batch F300460 of Biotax 1g injection was tested in Nepali laboratories before its sale and distribution in the country was suspended. This antibiotic, used to treat bacterial infections of the brain, lungs, ear, urinary tract, skin, soft tissue, blood, bones, joints and soft cells, was deemed unsafe by the Nepali Drug Authority. They warned that the batch tested posed a significant risk to patient safety.

According to Nepal’s drug authority, the batch tested is considered unsafe for use and poses a potential risk to patients’ lives.